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Abstract 
Background. Autophagy is an intracellular bulk degradation process induced by cell 
starvation. Autophagy was recently reported to be induced by various stresses such as 
hypoxia, ischemia/reperfusion, toxins, and denatured proteins, and to affect cell 
survival and death. Light chain 3-II (LC3-II) is specifically located on double 
membrane-bound autophagosomes that envelop disused proteins or organelles. 
Method. Transgenic mice in which green fluorescent protein (GFP) was fused to LC3 
(LC3-GFP) were administered cisplatin (20 mg/kg). After euthanasia at times 
between 0-72 hours, kidneys were excised for immunohistochemical analyses. 
Microscopic examinations of the generated NRK-52E cell lines stably transfected 
with LC3-GFP, and western blot analyses of NRK-52E cells were undertaken after 
cisplatin treatment with or without autophagy inhibitors and beclin 1 siRNA.  
Results. Autophagosomes increased in the proximal tubular cells of transgenic mice 
from 12 hours after cisplatin injection (20 mg/kg). The time course for this was faster 
than those for tubular necrosis and apoptosis. Autophagosomes also increased in 
NRK-52E cells after cisplatin treatment, with the time course for this faster than that 
for apoptosis. When autophagy was suppressed by autophagy inhibitors or beclin 1 
siRNA, the level of apoptosis was also suppressed. 
Conclusion. Autophagy occurs in proximal tubular cells after cisplatin treatment and 
is involved in cell death in renal tubular injury. Our data suggested that autophagy is a 
kind of cell damage index and cells with activated autophagy will be scavenged by 
apoptosis. 
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Introduction 
Eukaryotes have two major systems for degrading proteins: the 
ubiquitin-proteasome system and autophagy. The ubiquitin-proteasome system 
degrades short-lived and selective proteins. Autophagy degrades long-lived and 
non-selective proteins in large amounts and cell organelles. Autophagy is induced by 
starvation, changes in cell volume, oxidative stress, accumulation of misfolded 
proteins, hormonal signaling, irradiation and xenobiotic treatment [1,2], and the roles 
of autophagy have been suggested to include nutrition, recycling of amino acids, 
purification and cellular defense against bacteria. Macroautophagy is the most 
common form of autophagy, progressing through double-membrane autophagosomes. 
The discovery of autophagy-related proteins in yeast has revealed the existence of an 
evolutionarily conserved mechanism for the formation of autophagosomes that 
sequester cytoplasmic material before they fuse with the endo/lysosomal 
compartment [3,4]. Light chain 3-II (LC3-II) is specifically located on double 
membrane-bound autophagosomes that envelop disused proteins or organelles. 
LC3-II is a good marker for autophagic membranes. Mizushima et al. confirmed that 
over-expression of a fusion protein between green fluorescent protein and light chain 
3 (LC3-GFP) does not affect endogenous autophagy, and generated transgenic mice 
that systemically expressed this fusion protein (LC3-GFP mouse). Autophagosomes 
can be recognized as ring-shaped structures by fluorescence microscopy. Using these 
transgenic mice, autophagy in mouse tissues can be directly monitored by simply 
creating cryosections and subsequent fluorescence microscopy [5]. 
In neurodegenerative disorders, autophagy has been shown to contribute to the 
elimination of misfolded accumulated proteins [1,2]. Autophagy is induced in variant 
cancer cells in response to anticancer therapies, in some cases promotes cell survival 
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and in other cases induces apoptosis or type-2 programmed cell death [6-8]. Chronic 
myocardial ischemia/reperfusion injury induces autophagy increment and apoptosis 
decrement [9]. Inhibition of autophagy prevents neuron death after hypoxic-ischemic 
injury in neonatal mice [10]. However, in acute kidney injury (AKI), the association 
between autophagy and cell death is not obvious. 
Cisplatin is a major chemotherapeutic drug against solid tumors. One of the most 
important side effects of cisplatin is nephrotoxicity. Cisplatin is freely filtered at the 
glomerulus and taken up by renal tubular cells. There are many signaling cascades 
leading from cisplatin administration to AKI, for example, decreasing renal blood 
flow, levels of free radical scavengers, regulating expression of genes, increasing the 
numbers of inflammatory cells and levels of caspase-dependent apoptosis. Recently, 
the level of apoptosis was found to be related to the degree of seriousness of AKI 
[11]. 
The purpose of this study was to investigate the roles of autophagy in tubule cells 
in AKI to identify a procedure that modifies kidney damage. Our results indicated 
that cisplatin induces autophagy in proximal tubular cells in vivo. Inhibition of 
autophagy led to down-regulation of cisplatin-induced apoptosis in proximal tubular 
cells in vitro. Autophagy inhibitors may serve as therapeutic targets for the treatment 
of AKI. 
 
Subjects and Methods 
Materials 
Anti-light chain 3 antibody was purchased from MBL (Nagoya, Japan). 
Anti-aquaporin-1 antibody was purchased from Abcam (Cambridge, MA). 
Anti-cleaved caspase 3 and rapamycin were purchased from Cell Signaling (Danvers, 
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MA), anti-beclin 1 was purchased from BD Bioscience (Franklin Lakes, NJ), 
Lipofectamine™ 2000 was purchased from Invitrogen (Carlsbad, CA), 
3-methyladenine (3-MA) was purchased from SIGMA (Saint Louis, MI), 
[L-3-trans-ethoxycarbonyloxirane-2-carbony1]-L-leucine (3-methylbutyl) amide 
(E64d) and isovaleryl-L-Val-L-Val-AHMHA-L-Ala-AHMHA (pepstatin A) were 
purchased from PEPTIDE INSTITUTE, INC, (Osaka, Japan). Can Get Signal™ was 
purchased from TOYOBO (Osaka, Japan). 
 
Animal Preparation 
All experimental procedures were performed according to the guidelines for the 
care and use of animals established by Tokyo Medical and Dental University. Male 
transgenic mice that systemically expressed green fluorescent protein fused to light 
chain 3 (LC3-GFP mice; kind gift of Noboru Mizushima, Tokyo Medical and Dental 
University, Japan) [12] aged 21-22 weeks and weighing 35-40 g were used for the 
experiments. The mice underwent administration of cisplatin (20 mg/kg); the dose of 
cisplatin was determined on the basis of the results of previous studies in mice [13]. 
Kidney samples were harvested at the indicated times. The left kidney was perfused 
with chilled saline and fixed in 4% buffered paraformaldehyde for histological 
examination. 
 
Cell Culture 
The NRK-52E cell line was obtained from ATCC (Manassas, VA), and cultured in 
DMEM medium containing 10% fetal bovine serum, 100 units/ml penicillin, and 100 
g/ml streptomycin at 37°C in a 5% CO2 incubator. In harvesting experiments, the 
cells were seeded into 10-cm plastic dishes. In fluorescence microscopy experiments, 
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the cells were seeded in 35-mm glass-bottomed dishes. The LC3-GFP plasmid (kind 
gift of Noboru Mizushima, Tokyo Medical and Dental University, Japan) was 
transfected by electroporation on the basis of the results of previous studies [14]. 
NRK-52E cells (1.0 X 10
7
 cells) suspended in K-PBS were electroporated (360 V, 
960 FD) using a Gene Pulser (Bio-Rad, New York, NY). After transfection, the cells 
were cultured in medium containing 1 g/L G418. 
 
Fluorescence Microscopy 
We used an Olympus IX 81 microscope. We labeled tissues on the basis of the 
results of previous studies [13]. We used an Annexin V-Cy3 Apoptosis Detection Kit 
purchased from BioVision Research Products (Mountain View, CA) to detect 
apoptosis in vitro. We washed cells with PBS once, added 100 l of annexin V-Cy3 
in binding buffer (1:100) for 5 minutes in the dark, washed with PBS once, added 100 
l of 2% paraformaldehyde, incubated for 5 minutes in the dark, washed cells with PBS 
twice, and observed the cells within about 30 minutes. 
 
Beclin 1 Knockdown Using Small Interfering RNA 
A beclin 1 small interfering RNA (siRNA) and scrambled siRNA were purchased 
from Japan Bio Services Co., LTD. (Saitama, JAPAN). The siRNA sequence against 
beclin 1 was GAUUGAAGACACAGGAGGC [15]. The sequence of the scrambled 
siRNA was UCUGAAGAGGGGACCUAUCTT. NRK-52E cells were transfected
 
using Lipofectamine™ 2000. The control siRNA scrambled siRNA sequence) was 
used under identical conditions to the beclin 1 siRNA. To determine the efficiency of 
beclin 1 knockdown,
 
Western blot analyses for beclin 1 were performed. 
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NRK-52E cells were transfected with 125 nM siRNA for 4 hours from 56 hours 
before harvest; after transfection of cells with siRNAs, we changed the medium to 
DMEM without fetal bovine serum, penicillin and streptomycin for 4 hours. We 
changed the medium to DMEM containing 10% fetal bovine serum, but without 
penicillin and streptomycin, 48 hours before harvest, and administered 10 M 
cisplatin 24 hours before harvest. 
 
Western Blot Analyses 
Whole cell lysates were extracted from cultured NRK-52E cells lysed in sodium 
dodecyl sulfate (SDS) sample buffer using previously described methods [13]. Lysate 
proteins (60 g/lane) were separated on SDS-polyacrylamide gels and transferred to 
Hybond-ECL (GE Healthcare, Chicago, IL). The blots were incubated with the 
indicated antibodies (from 1:500 to 1:2000 dilution) overnight, followed by 
incubation with horseradish peroxidase-conjugated secondary antibodies (1:3000 
dilution) for 1 hour. Membranes were visualized using Western Blue (Promega, San 
Luis, CA). The intensities of the bands were quantified using Molecular Dynamics 
ImageQuant software (Sunnyvale, CA). At harvest, the cells were lysed for 30 
minutes on ice in 150 mM NaCl, 15 mM Tris-HCl, 25 mM NaF, and 1 mM Na3VO4 
(pH 8.0). 
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Statistical Analyses 
All values are expressed as means ± SEM. Statistical comparisons of differences 
were performed using one- or two-way analysis of variance (ANOVA) combined 
with the Newman-Keuls post hoc test. P< 0.05 was considered significant. 
 
Results 
Cisplatin Induces Macroautophagy in Proximal Tubular Cells In Vivo 
We first examined the conditions required to induce autophagy and where 
autophagy was induced using generated transgenic mice that systemically expressed a 
fusion protein between green fluorescent protein and light chain 3 (LC3-GFP mouse). 
At 12-48 hours after cisplatin (20 mg/kg) treatment of LC3-GFP mice, the numbers of 
autophagosomes were increased in proximal tubular cells compared with those of 
control mice (Figure 1 and 2). The numbers of autophagosomes were increased from 
12 hours, peaked at around 48 hours, and decreased after 72 hours. 
Immunohistochemistry for aquaporin-1 (AQP1), a marker of proximal tubular cells, 
revealed that the numbers of autophagosomes were increased in AQP1-positive cells. 
The change in the number of autophagosomes was not significant in the medulla 
(Figure 3). We also performed immunohistochemistry for cleaved caspase 3, a marker 
of the early phase of apoptosis. The increase in the numbers of autophagosomes 
preceded an increase in the amount of cleaved caspase 3 that was observed 24-48 
hours after cisplatin treatment (Figure 4). 
 
Cisplatin Induces Macroautophagy in Cultured Proximal Tubular Cells 
Next, we used NRK52-E cells, a proximal tubular cell line, to investigate the 
effects of cisplatin in vitro. Hanks’ balanced salt solution treatment as a starvation 
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condition induced an increase in the numbers of autophagosomes in NRK52-E cells 
stably transfected with a fusion protein between green fluorescent protein and light 
chain 3 (LC3-GFP NRK cells) (Figure 5A), and generation of LC3-II in Western blot 
analyses of protein from non-transfected NRK52-E cells (Figure 5B). Addition of 
cisplatin to DMEM medium induced an increase in the numbers of autophagosomes 
and generation of LC3-II to a similar level than the starvation condition. These 
changes preceded positive staining for annexin V and cleaved caspase 3, a marker of 
the early phase of apoptosis. The generation of LC3-II was increased dose and time 
dependently up to 48 hours (Figure 6 and 7). 
 
Cisplatin-Induced Apoptosis Is Suppressed by Inhibition of Macroautophagy in 
Proximal Tubular Cells 
To examine the involvement of autophagy in the apoptotic pathway, we employed 
chemical inhibitors and a stimulator of autophagy. We used 3-methyladenine (3-MA), 
which is widely used as an autophagy inhibitor, as an inhibitor of autophagosome 
formation [16]. We also used inhibitors of lysosomal proteases including 
[L-3-trans-ethoxycarbonyloxirane-2-carbony1]-L-leucine (3-methylbutyl) amide 
(E64d), a calpain inhibitor, and isovaleryl-L-Val-L-Val-AHMHA-L-Ala-AHMHA 
(pepstatin A), a cathespsin D inhibitor [17]. On the other hand, rapamycin was used to 
induce autophagosome formation [18]. 
We treated LC3-GFP NRK cells with these inhibitors and rapamycin at the same 
time as adding 40 M cisplatin. Twenty hours after administration, the 
cisplatin-induced increase in the numbers of autophagosomes was enhanced by 
rapamycin and E64d/pepstatin A compared with control cells. On the other hand, the 
cisplatin-induced increase in the numbers of autophagosomes was depressed by 
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3-MA compared with control cells. Cisplatin-induced apoptosis was observed as 
annexin V staining, which was enhanced by rapamycin and suppressed by 3-MA and 
E64d/pepstatin A (Figure 8). 
Furthermore, we examined generation of LC3-II in NRK52-E cells. Similar to the 
results of fluorescence microscopy, generation of LC3-II was enhanced by rapamycin 
and E64d/pepstatin A compared with controls. On the other hand generation of 
LC3-II was depressed by 3-MA compared with controls. At the same time we 
performed Western blot analyses of cleaved caspase 3 as a marker of 
cisplatin-induced apoptosis. Levels of cleaved caspase 3 were not changed by 
rapamycin, but were significantly depressed by 3-MA and E64d/pepstatin A (Figure 
9B). In the absence of cisplatin, band intensity of cleaved caspase 3 increased by 
3-MA. This increment may reflect cell damage and cell death by 3-MA in this 
experimental condition. 
. 
 
Cisplatin-Induced Apoptosis Is Suppressed by Specific Inhibition of Macroautophagy 
by beclin 1 siRNA 
To more specifically inhibit autophagy, we used beclin 1 small interfering RNA 
(siRNA). Beclin 1 is the mammalian homolog of Atg 6 and forms a complex with 
class III phosphatidylinositol 3-kinase (PI3 kinase) [19]. Beclin 1 siRNA suppressed 
the production of beclin 1, and the 10 M cisplatin-induced enhancement of cleaved 
caspase 3 levels was suppressed significantly by the beclin 1 siRNA (Figure10). 
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Discussion 
This is the first study to demonstrate a relationship between macroautophagy and 
apoptosis in renal tubular cells by fluorescence microscopic examination using the 
LC3-GFP mouse. We demonstrated the formation of autophagosomes during 
cisplatin-induced AKI in vivo, and indicated that cisplatin-induced autophagy 
occurred faster than apoptosis in proximal tubules. 
The form of LC3 with a glycine residue at the C-terminal end, termed LC3-I, 
resides in the cytosol. After activation, the final form of LC3 is designated LC3-II, 
which associates tightly with the autophagosomal membrane [5]. Because 
autophagosomes are constantly recycled, and so are transient structures, the lifetime 
of LC3-II from activation to decomposition is relatively short. The level of LC3-II 
represents only the autophagic activity at that moment, and does not indicate the 
quantity of flow through the autophagic pathway. We examined autophagy with or 
without cisplatin in the presence of E64d and pepstatin A. The numbers of 
autophagosomes and the amount of LC3-II were increased by cisplatin. We 
concluded that cisplatin increased flow through the autophagic pathway [5,17]. 
We demonstrated in this paper that inhibition of autophagy suppressed 
cisplatin-induced apoptosis. Our data clearly showed that autophagy precedes 
apoptosis, and that inhibition of autophagy using two inhibitors or beclin 1 siRNA 
suppressed apoptosis. 3-MA is thought to induce its effects via its activity as a class 
III PI3 kinase inhibitor [16]; however it is not only a specific inhibitor of 
macroautophagy, it also has effects on membrane trafficking, alkalinizes the 
lysosomal lumen, and can inhibit the phosphorylation of JNK and p38 [5]. In the 
absence of cisplatin, band intensity of cleaved caspase 3 increased by 3-MA as shown 
in the Figure 9A. This increment may reflect cell damage and cell death by 3-MA, 
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because inhibition of autophagy with 3-MA was reported to sensitize HeLa cells to 
starvation-induced cell death in some condition [6, 15]. In the presence of cisplatin, 
levels of cleaved caspase 3 were significantly depressed by 3-MA and E64d/pepstatin 
A (Figure 9B). Thus we believe that inhibition of autophagy down-regulates 
cisplatin-induced apoptosis in proximal tubular cells in vitro at least in our 
experimental conditions. 
Furthermore, we performed experiments with the protease inhibitors E64d and 
pepstatin A, and with beclin 1 siRNA, obtaining similar results. 
Why does inhibition of autophagy suppress cisplatin-induced apoptosis? There are 
many possibilities. In a recent in vivo study, Koike et al. indicated that deficiency of 
Atg7 prevented hippocampal pyramidal neuron death in hippocampi from neonatal 
mouse brains after hypoxic-ischemic injury [10]. Also, several studies have reported 
that autophagy and one or more proapoptotic genes (for example, BAX) collaborate 
to promote cell death [20-22]. The proapoptotic genes may switch from cell 
protective autophagy to injurious autophagy promoting cell death. We will investigate 
the relationships among autophagy, proapoptotic genes and apoptosis in future studies. 
Why does autophagy yield apoptosis? The inhibition of autophagy increases the 
mutation rate in yeast [23]. In conditions of chronic stress induced by limited 
resources (for example, starvation, dehydration and chronic ischemia), scavenging 
more damaged cells by activating autophagy can reduce the consumption of limited 
resources. But if the duration of the stress were short, scavenging might eliminate 
recoverable cells. 
Recently, Yang et al. and Periyasamy-Thandavan et al, indicated that inhibition of 
cisplatin-induced autophagy enhanced cisplatin-induced apoptosis [24, 25]. Their 
report was the first report to indicate a relationship between autophagy and apoptosis 
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13 
in kidney cells; however, they did not perform in vivo experiments. Our report is the 
first to include in vivo experiments. The results of Yang et al. regarding the 
relationship between autophagy and apoptosis show some discrepancy with our 
results. There are many possible explanations for this discrepancy. One possibility is 
the difference in cell types, another is the difference in autophagy inhibitors used, and 
a third possibility is the concentration and timing of siRNAs. Yang et al. used 
LLC-PK1 cells, and wortmannin, which inhibits class I, II, and III PI3 kinase 
members nonspecifically and enhances apoptosis through the inhibition of PI3 
kinase/Akt signal transduction cascade, was used to inhibit autophagy [13, 26-27]. 
Thus, this discrepancy may indicate the balance between the anti-apoptotic effect of 
the class I PI3 kinase-Akt pathway and apoptotic facilitation of the class III PI3 
kinase-autophagy pathway. The period during transfection of siRNA and cisplatin 
administration was different between our study and theirs. The timing of depression 
of the target protein and the cisplatin-induced apoptosis pathway also might not 
match. Also, the concentration of siRNA was different between our study and theirs. 
A high concentration of siRNA might injure cells and induce apoptosis.  
Recent report by Suzuki et al. demonstrated that an increase in autophagosomes in 
the renal tubular epithelial cells of ischemic/reperfusion injury in mouse model and in 
cultured renal tubular cells under hypoxic condition [28]. Our results accord with this 
study concerning renal tubular injury and autophagy. 
In conclusion, our results indicated that cisplatin induces autophagy in proximal 
tubular cells in vivo, and that inhibition of autophagy down-regulates 
cisplatin-induced apoptosis in proximal tubular cells in vitro. Autophagy inhibitors 
may serve as therapeutic targets for the treatment of AKI. 
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Figure Legends 
Figure 1. Time course of cisplatin-induced macroautophagy in the cortex in vivo. 
Transgenic mice expression a fusion protein between green fluorescent protein and 
light chain 3 (LC3-GFP mice) underwent 20 mg/kg cisplatin administration. Kidney 
samples were harvested at 0, 12, 24, 48 and 72 hours after cisplatin administration. 
The upper panels show low-power views (original magnification x400), and the lower 
panels show high-power views (original magnification x600). The arrows indicate the 
autophagosomes. Autophagosomes increased from 12 hours, peaked at 48 hours, and 
decreased after 72 hours. At 48 hours after cisplatin administration, kidneys showed 
severe loss of tubular epithelial cells. 
 
Figure 2. Cortex immunostained for AQP1 after cisplatin administration in vivo. 
Transgenic mice underwent 20 mg/kg cisplatin administration. Kidney samples were 
harvested at 0 and 24 hours after cisplatin administration. (A) Zero hours after 
cisplatin administration. (B) Twenty-four hours after cisplatin administration. Left 
panels indicate autophagosomes containing LC3-GFP. The arrows indicate the 
autophagosomes. Center panels show immunostaining with anti-aquaporin-1 
(anti-AQP1) antibody. The arrows indicate AQP1-positive cells. Right panels show 
merges (original magnification x400 and x600). Positive staining for AQP1 was 
detected at proximal tubular cells. Proximal tubular cells with strong injury showed 
decreased AQP1 expression 24 hours after cisplatin administration. (C) Higher 
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magnification view of the cortex labeled with anti-AQP1 antibody 24 hours after 
cisplatin administration. Autophagosomes were present in proximal tubular cells 24 
hours after cisplatin administration. 
 
Figure 3. Medulla labeled with an antibody against AQP1 after cisplatin 
administration in vivo. Transgenic mice underwent 20 mg/kg cisplatin administration. 
Kidney samples were harvested at 0 and 24 hours after cisplatin administration. (A) 
Zero hours after cisplatin administration. (B) Twenty-four hours after cisplatin 
administration. Left panels indicate autophagosomes containing LC3-GFP. Center 
panels show immunostaining with anti-AQP1 antibody. Right panels show merges 
(original magnification x400 and x600). No cells showed an increase in the numbers 
of autophagosomes after cisplatin administration. 
 
Figure 4. Time course of cisplatin-induced macroautophagy and staining with 
anti-cleaved caspase 3 antibody in cortex in vivo. Transgenic mice underwent 20 
mg/kg cisplatin administration. Kidney samples were harvested at 0, 12, 24, 48 and 
72 hours after cisplatin administration. Upper panels indicate autophagosomes with 
LC3-GFP. The arrows indicate the autophagosomes. Center panels show 
immunostaining with anti-cleaved caspase 3 antibody. The arrows indicate cleaved 
caspase 3-positive cells. Lower panels show merges (original magnification x400). 
Positive staining of cleaved caspase 3 was detected in cells in the early phase of 
apotosis. The increase in the numbers of autophagosomes was seen from 12 hours 
after cisplatin administration. Cells with positive cleaved caspase 3 staining were seen 
24-48 hours after cisplatin administration. 
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Figure 5. Hanks’ balanced salt solution treatment as a starvation condition induced 
autophagy in proximal tubular cells in vitro. (A) NRK52-E cells stably transfected 
with a fusion protein between green fluorescent protein and light chain 3 were treated 
with Hanks’ balanced salt solution for 0 or 30 minutes. Hanks’ balanced salt solution 
treatment induced an increase in the numbers of autophagosomes (original 
magnification x400). (B) Western blots of protein from NRK52-E cells treated with 
Hanks’ balanced salt solution for 0 or 2 hours, with or without 
[L-3-trans-ethoxycarbonyloxirane-2-carbony1]-L-leucine (3-methylbutyl) amide 
(E64d) and isovaleryl-L-Val-L-Val-AHMHA-L-Ala-AHMHA (pepstatin A). Hanks’ 
balanced salt solution treatment induced generation of LC3-II. 
 
Figure 6. Addition of cisplatin to DMEM medium induced autophagy in LC3-GFP 
stably transfected proximal tubular cells in vitro. NRK52-E cells stably transfected 
with a fusion protein between green fluorescent protein and light chain 3 were treated 
with 40 M cisplatin for 0, 3, 6 (early phase), 12, 24 or 48 (late phase) hours before 
observation. The upper panels indicate autophagosomes containing LC3-GFP. The 
arrows indicate the autophagosomes. Center panels show staining with anti-annexin V 
antibody. The arrows indicate annexin V-positive cells. Lower panels show merges 
(original magnification x400). The increase in the numbers of autophagosomes 
occurred from 3 or 6 hours after cisplatin treatment. Positive staining for annexin V at 
membrane surface was detected from 12 hours. 
 
Figure 7. Addition of cisplatin to DMEM medium induced autophagy in proximal 
tubular cells in vitro in Western blot analysis. (A) Western blots of protein from 
NRK52-E cells treated with 18 M cisplatin for 0, 12, 24 or 48 hours before harvest. 
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The generation of LC3-II was increased time dependently up to 48 hours. The cleaved 
caspase 3 was increased time dependently up to 48 hours. (B) Western blots of 
protein from NRK52-E cells treated with cisplatin at 0, 7.5, 10, 15 or 20 M for 48 
hours. The generation of LC3-II was increased dose dependently. The cleaved 
caspase 3 was increased dose dependently. 
 
Figure 8. Cisplatin-induced apoptosis was suppressed by inhibition of 
macroautophagy in LC3-GFP stably transfected proximal tubular cells in vitro. (A) 
NRK52-E cells stably transfected with a fusion protein between green fluorescent 
protein and light chain 3 were treated with rapamycin (100 nM), 3-methyladenine 
(3-MA) (10 mM), or E64d (29.6 M) /pepstatin A (14.6 M) for 20 hours without 
cisplatin. There was an increase in the numbers of autophagosomes in cells treated 
with rapamycin or E64d/pepstatin A, but no cells showed positive staining for 
annexin V at the membrane surface without cisplatin. (B) NRK52-E cells stably 
transfected with a fusion protein between green fluorescent protein and light chain 3 
were treated with rapamycin (100 nM), 3-MA (10 mM), or E64d (29.6 M) /pepstatin 
A (14.6 M) for 20 hours and with cisplatin (40M) for 20 hours before observation. 
The increase in the number of autophagosomes was enhanced by rapamycin and 
E64d/pepstatin A, and depressed by 3-MA compared with controls. The positive 
staining for annexin V at the membrane surface was enhanced by rapamycin and 
suppressed by 3-MA and E64d/pepstatin A. (A and B) Upper panels indicate 
autophagosomes containing LC3-GFP. The arrows indicate the autophagosomes. 
Center panels show staining with anti-annexin V antibody. The arrows indicate 
annexin V-positive cells. Lower panels show merges (original magnification x400). 
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Figure 9. Cisplatin-induced apoptosis is suppressed by inhibition of macroautophagy 
in proximal tubular cells in vitro in Western blot analyses. (A) Western blots of 
protein from NRK52-E cells treated with rapamycin (100 nM), 3-MA (10 mM), or 
E64d (29.6 M) /pepstatin A (14.6 M) for 24 hours without cisplatin. (B) Graph 
summaries of Figure 9A using a densitometer. Each bar represents the mean ± SEM. 
(C) Western blots of protein from NRK52-E cells treated with rapamycin (100 nM), 
3-MA (10 mM), or E64d (29.6 M) /pepstatin A (14.6 M) for 24 hours with 18 M 
cisplatin. The generation of LC3-II was enhanced by rapamycin, and E64d/pepstatin 
A, and depressed by 3-MA compared with controls. (D) Graph summaries of Figure 
9C using a densitometer. Each bar represents the mean ± SEM (n = 5). *P < 0.01 vs. 
only cisplatin. Cleaved caspase 3 was unchanged by rapamycin, and significantly 
depressed by 3-MA and E64d/pepstatin A. 
 
Figure 10. Cisplatin-induced apoptosis is suppressed by specific inhibition of 
macroautophagy by beclin 1 siRNA in vitro. (A) Western blots of protein from 
NRK52-E cells treated with scrambled siRNA or beclin 1 siRNA. Beclin 1 siRNA 
suppressed the expression of beclin 1. Graph summaries of Western blots using a 
densitometer are also shown. Each bar represents the mean ± SEM (n = 4). *P < 0.01 
vs. control. (B) Western blots of protein from NRK52-E cells treated with scrambled 
siRNA or beclin 1 siRNA with or without 10 M cisplatin, and graph summaries of 
Western blots using a densitometer. Each bar represents the mean ± SEM (n = 4). *P 
< 0.05 vs. control plus cisplatin. The cisplatin-induced enhancement of cleaved 
caspase 3 was suppressed by beclin 1 siRNA. 
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